molnupiravir

Molnupiravir, trade name Lagevrio, is one of two COVID oral antivirals on the market, the other being Paxlovid.

About two months ago, when Pfizer's Paxlovid (1) was first distributed to a very select group of pharmacies throughout the US, you pretty much had to know the Pope (and perhaps his pharmacist) to get your hands the

I recently wrote an article comparing the availability and use of the two newly approved anti-COVID drugs (1) Paxlovid and molnupiravir. Bottom line: Doctors and patients voted with their scripts.

Just for laughs (and what could possibly be more fun than this?), I called a bunch of local pharmacies to see whether any of them had a supply of the two newly-approved (1) antiviral COVID medications.

The Food and Drug Administration recently granted Emergency Use Authorization (EUA) to Paxlovid and molnupiravir, two lifesaving, direct-acting antiviral drugs that are effective in preventing both hospitalization and death of people who have cont

Following the FDA's granting of Emergency Use Authorization to Merck's molnupiravir and Pfizer's Paxlovid, the only two approved direct-acting antiviral drugs; we now have two badly needed tools to deal with COVID, especially since it is

It's not totally absurd to compare our war against COVID with a boxing match. The virus clearly won Round 1; aside from masks and isolation, we were pretty much defenseless.

Putting aside the usual anti-pharma narrative for a moment, Merck, which is seeking emergency use authorizat

There are now two direct-acting antiviral drugs that have been shown to decrease the severity of COVID, Gilead's remdesivir and Merck's molnupiravir.

The race to discover anti-COVID drugs, just like the race to discover any drugs, has been long (1) and frustrating.